Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/58869
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDavid V. Gliddenen_US
dc.contributor.authorKathleen Mulliganen_US
dc.contributor.authorVanessa McMahanen_US
dc.contributor.authorPeter L. Andersonen_US
dc.contributor.authorJuan Guaniraen_US
dc.contributor.authorSuwat Chariyalertsaken_US
dc.contributor.authorSusan P. Buchbinderen_US
dc.contributor.authorLinda Gail Bekkeren_US
dc.contributor.authorMauro Schechteren_US
dc.contributor.authorBeatriz Grinsztejnen_US
dc.contributor.authorRobert M. Granten_US
dc.date.accessioned2018-09-05T04:34:20Z-
dc.date.available2018-09-05T04:34:20Z-
dc.date.issued2018-07-18en_US
dc.identifier.issn15376591en_US
dc.identifier.issn10584838en_US
dc.identifier.other2-s2.0-85048510668en_US
dc.identifier.other10.1093/cid/ciy083en_US
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85048510668&origin=inwarden_US
dc.identifier.urihttp://cmuir.cmu.ac.th/jspui/handle/6653943832/58869-
dc.description.abstract© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. Background Antiretroviral drugs have been associated with changes in lipids, fat mass and dat distribution. Tenofovir disoproxil fumarate (TDF) has been shown to have a more favorable metabolic profile than other drugs in its class. However, the metabolic effects of TDF in preexposure prophylaxis (PrEP) are unknown. Methods We evaluated the effects of TDF/emtricitabine (FTC) on lipids and body composition in a blinded, placebo-controlled PrEP trial. Participants enrolled in a metabolic subcohort (N = 251, TDF/FTC; N = 247, placebo) consented to fasting lipid panels, dual-energy X-ray absorptiometry scans for body composition, and pharmacologic testing of drug metabolites at baseline and every 24 weeks thereafter. Results Lean body mass was stable and unaffected by TDF/FTC. Body weight increased in both groups but was lower on TDF/FTC through week 72. This difference was explained by lower fat accumulation on TDF/FTC. The net median percent difference (standard error, P value) for TDF/FTC vs placebo at week 24 was -0.8% (0.4%, P =.02),+0.3% (0.4%, P =.46), and -3.8% (1.4%, P =.009) for total, lean, and fat mass, respectively. There was no apparent differential regional fat accumulation on TDF/FTC. Decreases in cholesterol, but not triglycerides, were seen in TDF/FTC participants, with detectable drug levels compared to placebo. Conclusions TDF/FTC for PrEP showed cholesterol reductions and appeared to transiently suppress the accumulation of weight and body fat compared to placebo. There was no evidence of altered fat distribution or lipodystrophy during daily oral TDF/FTC PrEP.en_US
dc.subjectMedicineen_US
dc.titleMetabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabineen_US
dc.typeJournalen_US
article.title.sourcetitleClinical Infectious Diseasesen_US
article.volume67en_US
article.stream.affiliationsUniversity of California, San Franciscoen_US
article.stream.affiliationsUniversity of Washington, Seattleen_US
article.stream.affiliationsUniversity of Colorado at Boulderen_US
article.stream.affiliationsInvestigaciones Medicas en Saluden_US
article.stream.affiliationsChiang Mai Universityen_US
article.stream.affiliationsSan Francisco Department of Public Healthen_US
article.stream.affiliationsDesmond Tutu HIV Foundationen_US
article.stream.affiliationsHospital Escola Sao Francisco de Assisen_US
article.stream.affiliationsFundacao Oswaldo Cruzen_US
article.stream.affiliationsGladstone Institute of Virologyen_US
article.stream.affiliationsSan Francisco AIDS Foundationen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.